PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker Abstract #79
Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.
Aim(s): As PTOV-1 has not yet been studied in neuroendocrine tumors (NETs), the aim of this research was to carry out an immunohistochemical study on a large cohort of neuroendocrine tumors of different origin, in order to evaluate this novel oncogenic factor in NETs.
Materials and methods: Eighty NETs of distinctive origin were selected: 12 medullary thyroid carcinomas, five Merckel carcinomas (four skin, one vulva), 21 small cell carcinomas (two bladder, one ovary, 18 lung), one large cell neuroendocrine carcinoma (lung), 11 pheocromocytomes, 25 GEP-NET (10 appendix, four small bowel, 11 pancreas) and five NET lymph nodal metastases. Immunohistochemical assay with PTOV-1 (home-made polyclonal 1:40 dilution) and chromogranin A (monoclonal, Dako; 1:50 dilution) with Envision method was performed on formalin-fixed paraffin-embedded sections. Intensity and percentage of immunostaining was evaluated by the HScore (scale 1 to 300), considering overexpression > 100. Data were analyzed with SPSS16.0, using U Mann-Whitney and Spearman tests.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: MD INES DE TORRES
To read results and conclusion, please login ...
Further abstracts you may be interested in
#445 Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC
Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Dra Nuria Mulet-Margalef
#866 Plasma Chromogranin B as a Marker of Tumor Burden and Radiological Progression in Neuroendocrine Tumors
Introduction: Chromogranin-B (CgB) is expressed in most neuroendocrine tumors (NETs), yet little is understood about its clinical utility as a biomarker.
Conference: 11th Annual ENETS Conference (2014)
Presenting Author: David Braude
Introduction: Chromogranin B (CgB) co-localizes with Chromogranin A (CgA) in the secretory granules of neuroendocrine cells. Previous studies have investigated CgA, but not CgB, as a prognostic marker in NETs.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Mr Paul R Bech
#1177 An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases
Introduction: Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed.
Conference: 12th Annual ENETS Conference (2015)
Presenting Author: Ron Basuroy
#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures
Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: doctor Corinne Gerard